The cheapest way to get GLP-1 medication in 2026 depends on which lane you actually qualify for. If your commercial plan covers the drug, a manufacturer savings card can cut a fill to as little as $25 a month. If you have Medicare Part D and meet the program’s BMI rules, the Medicare GLP-1 Bridge charges a $50 monthly copay for Wegovy, Zepbound, or Foundayo through December 31, 2027. If you are paying cash, the cheapest brand-name starting prices as of October 2026 are the Wegovy pill and Foundayo at $149 a month at their lowest doses. [4] [5] [6] [16] [17] [18]
All prices in this article are tracked in our monthly GLP-1 Price Index.
The hard part is that cheap GLP-1 access is full of false comparisons. A number can look low because it is only an intro month. It can look low because the membership fee excludes medication. It can look low because the product is compounded rather than FDA-approved. Or it can look low because the site never tells you the actual dose well enough to compare it honestly.
This guide is built for the reader who wants the real decision tree, not a soft-focus roundup. If you want the surrounding context first, open our telehealth comparison, insurance guide, Medicare coverage guide, and brand vs. compounded guide.
What Is the Cheapest Way to Get a GLP-1 in 2026?
If you want the short answer first, here is the ranking as of October 2026:
- Cheapest if you qualify, but only for Ozempic: Novo Nordisk’s patient assistance program (PAP) provides medicine at $0. Its 2026 product list includes Ozempic for uninsured patients only, with household income at or below 200% of the federal poverty level, and it does not list Wegovy. Ozempic is FDA-approved for type 2 diabetes, not for weight loss. [3] [15] [22]
- Cheapest if you already have usable coverage: manufacturer savings plus insurance can bring a covered Wegovy, Ozempic, Zepbound, or Foundayo fill to as little as $25 a month for eligible commercially insured patients. Each of those cards caps savings at $100 for a one-month fill, so a high copay can leave you paying more than $25. [4] [5] [6] [18]
- Cheapest if you have Medicare Part D: the Medicare GLP-1 Bridge charges a $50 monthly copay for Wegovy (pen or pill), the Zepbound KwikPen, or Foundayo for adults who meet its BMI rules, from July 1, 2026 through December 31, 2027. [16] [17]
- Cheapest insurance-first telehealth membership we found: Found’s Branded GLP-1 Plan costs $49 a month with insurance on a 12-month plan, or $89 on a one-month plan. The drug is billed separately, and insured visits usually carry a copay of about $30. [10] [24]
- Cheapest brand self-pay starting price: the Wegovy pill is $149 a month at 1.5 mg, $199 at 4 mg, and $299 at 9 mg or 25 mg. Foundayo is $149 a month at 0.8 mg and 2.5 mg, $199 at 5.5 mg, and $299 at 9 mg and above. The Foundayo 2.5 mg and 5.5 mg prices are temporary reductions through December 31, 2026. [4] [18]
- Cheapest transparent self-pay injectable: Zepbound is $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg to 15 mg if you refill within 45 days. Wegovy pens are $199 a month for the first two fills at 0.25 mg or 0.5 mg for new patients, then $349, or $399 for the 7.2 mg dose. [4] [6]
- Government and discount-card listings: TrumpRx.gov lists Wegovy, Ozempic, Zepbound, and Foundayo at the same prices as the manufacturers’ self-pay programs, and GoodRx’s Wegovy prices match Novo Nordisk’s ladder. Neither is a deeper discount. [7] [19] [21]
- Cheapest medication-included low-dose bundle we could verify: Noom’s Microdose GLP-1 Rx starts at $79 for the first 4 weeks, then $179 a month. Noom says the semaglutide in its GLP-1 Rx programs is compounded, and compounded drugs are not FDA-approved. [11] [1]
- Cheapest route people ask about but should not romanticize: international import or mail-order. FDA says importing drugs for personal use is illegal in most circumstances, with only narrow discretionary exceptions. [2]
How Much Does Each GLP-1 Option Cost per Month?
| Option | Monthly cost we verified (October 2026) | Biggest barriers | Timeline | Reliability |
|---|---|---|---|---|
| Patient assistance program | $0 for Ozempic, if you qualify. [3] [15] | Uninsured only for Ozempic, household income at or below 200% of the poverty level, and paperwork. Wegovy is not on the 2026 product list. | Slowest start because application and approval come first. | High if approved, but very narrow eligibility. |
| Insurance + manufacturer savings | As low as $25/month for eligible commercially insured Wegovy, Ozempic, Zepbound, or Foundayo fills, with savings capped at $100 for a one-month fill. [4] [5] [6] [18] | Only for eligible commercially insured patients; government beneficiaries excluded; the Zepbound and Foundayo cards end December 31, 2026 under current terms. | Fast if your plan already covers the drug and the card works. | High when the claim pays, but plan-dependent. |
| Medicare GLP-1 Bridge | $50/month copay. [16] [17] | Part D required; BMI rules; prior authorization; excludes people with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, and people already getting a GLP-1 through Part D. | Prior authorization comes first. | High while it runs, through December 31, 2027. |
| Insurance-linked telehealth | Found’s Branded GLP-1 Plan: $49 to $89/month with insurance, plus visit copays (typically about $30) and the drug’s cost. [10] [24] | Coverage still depends on your insurer and prior authorization; not available with government insurance. [24] | Usually faster than a local-office search, slower than pure cash pay. | High if you want help navigating coverage, but not always cheapest after cost sharing. |
| Discount card / government price site | GoodRx and TrumpRx.gov show the manufacturers’ self-pay prices, such as Wegovy from $149 and Zepbound from $299. [7] [19] | Self-pay only; the purchase does not count toward an insurance deductible or out-of-pocket limit. [5] [20] | Fast if you are paying cash and can fill immediately. | Medium to high: the prices are the manufacturer ladders, not separate deals. |
| Self-pay brand direct pricing | Wegovy pill $149 to $299; Foundayo $149 to $299 ($349 at the top doses after a late refill); Wegovy pen $199 intro, then $349 to $399; Zepbound $299 to $449. [4] [6] [18] | Still expensive if uninsured; prescription required; prices rise with dose; Lilly’s 45-day refill rules. | Usually the cleanest fast-start cash option. | High because the public price ladders are transparent. |
| Telehealth cash-pay bundle | Ro membership $39 first month, then $149/month (or $74 to $99 a month prepaid), with medication billed separately at manufacturer prices; Noom GLP-1 Rx starts at $129, then $279/month, with compounded medication included; Calibrate is $199/month with a 3-month commitment, medication and labs separate. [8] [11] [12] | You have to separate membership cost from medication cost. | Often quick, but intake and PA work still take time. | Medium to high, depending on whether the medication model is clear. |
| Compounded or microdose alternatives | Sometimes lower than brand starter pricing, including Noom Microdose at $79 for the first 4 weeks, then $179/month. [11] | Product type differs from a full-dose FDA-approved brand path; compounding adds quality and safety concerns. | Often marketed as fast. | Lower, because the cheap number may hide a different product or risk profile. [1] |
| Clinical trials | Sometimes low-cost or no-cost for the study intervention, but costs vary by protocol. [13] [14] | Eligibility, geography, consent, and uncertainty about what the study covers. | Slowest and most selective path. | Medium for access, low for convenience. |
| International or mail-order import | Sticker price can look low, but it is not a dependable legal shortcut. [2] | FDA import restrictions, customs risk, and source-quality risk. | Unpredictable. | Low. |
Path-by-Path Breakdown
1. Insurance-covered access is still the best bargain when it actually works
If your plan already covers the drug, the cheapest move is usually to stay inside that lane and add official savings on top. As of October 2026, Wegovy’s page says eligible commercially insured patients can pay as little as $25 per month, and the Ozempic and Zepbound savings pages say the same. [4] [5] [6] For card-by-card rules, see our savings card guide.
That does not mean every insured person pays $25. It means your final bill depends on four separate gates:
- whether the plan covers obesity treatment at all
- whether prior authorization is approved
- whether you meet the card’s commercial-insurance rules
- whether your copay fits under the card’s cap: the Wegovy, Ozempic, and Zepbound cards save at most $100 on a one-month fill, so a $200 copay would still leave about $100 to pay [4] [5] [6]
That is why a bland sentence like “use insurance first” is incomplete. Insurance is cheapest when the plan is already friendly. It is frustrating and slow when the benefit is excluded or the deductible is still biting.
2. Medicare Part D enrollees may qualify for the $50 GLP-1 Bridge
Medicare is no longer a dead end for weight-loss GLP-1s, at least for now. Under the Medicare GLP-1 Bridge, eligible Part D enrollees pay a $50 monthly copay for Wegovy (injection or tablet), Zepbound (KwikPen only), or Foundayo from July 1, 2026 through December 31, 2027. [16] [17]
The rules are specific:
- You need Medicare drug coverage, such as a standalone Part D plan or a Medicare Advantage plan with drug coverage. [17]
- You must be 18 or older and have a BMI of 35 or higher; or a BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled high blood pressure, or stage 3a or higher chronic kidney disease; or a BMI of 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. [17]
- You are not eligible if you already get a GLP-1 through your Part D plan, or if you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. Medicare says your Part D plan might cover a GLP-1 for those conditions instead. [17]
- Your prescriber has to complete a prior authorization. CMS says the Part D deductible does not apply, the $50 copay does not count toward your out-of-pocket total, and the low-income subsidy does not lower it. [16] [17]
CMS says the BALANCE Model is not launching in Medicare in 2027, so the Bridge was extended through December 31, 2027. [16] [26] For a step-by-step version, see our Medicare GLP-1 Bridge checklist.
3. Manufacturer savings are real, but they are not universal
The manufacturer-card math is straightforward only for a narrow group of patients. The self-pay side is clearer than it used to be, because each major brand now posts a dose-by-dose price.
- Wegovy: eligible commercially insured patients can pay as little as $25 per month, with savings capped at $100 a month. Self-pay Wegovy pills cost $149 at 1.5 mg, $199 at 4 mg, and $299 at 9 mg or 25 mg. Self-pay pens cost $199 a month for the first two fills of 0.25 mg or 0.5 mg for new patients (offer through December 31, 2026), then $349, or $399 for the 7.2 mg Wegovy HD pen. [4]
- Ozempic: eligible commercially insured patients can pay as little as $25, with savings capped at $100 a month, while self-pay pens cost $199 for the first two months of 0.25 mg or 0.5 mg for new patients, then $349, or $499 for 2 mg. [5]
- Zepbound: commercially insured patients whose plan covers the Zepbound single-dose pen can pay as little as $25 under a savings card that expires December 31, 2026. Self-pay pricing is $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg to 15 mg, for either a KwikPen or four vials a month. The $449 price on 7.5 mg and up applies only if each refill is completed within 45 days of the last delivery; otherwise the price is $499 for 7.5 mg and $699 for 10 mg to 15 mg. [6]
- Foundayo (orforglipron): Lilly’s once-daily pill is $149 a month at 0.8 mg and 2.5 mg, $199 at 5.5 mg, and $299 at 9 mg, 14.5 mg, and 17.2 mg. The 2.5 mg and 5.5 mg prices are temporary reductions through December 31, 2026 (regular prices $199 and $299), and the 14.5 mg and 17.2 mg doses go up to $349 if a refill is more than 45 days late. A commercial savings card can bring a covered fill to as little as $25, with savings capped at $100 a month and $1,000 a year, through December 31, 2026. [18] If you are weighing the pill, see where to get Foundayo.
The practical rule is simple: if a price only exists inside a savings-card eligibility box, do not treat it as a public market price. And if a self-pay price depends on refill timing, note the refill deadline before you buy.
4. GoodRx and TrumpRx.gov show the manufacturer prices, not a deeper discount
GoodRx is still worth checking because it shows the self-pay price at specific pharmacies. As of October 2026, its Wegovy page lists the pill from $149 at 1.5 mg, $199 at 4 mg, and $299 at 9 mg and 25 mg, and pens at $199 for the intro doses, $349 for 1 mg to 2.4 mg, and $399 for 7.2 mg. Those match Novo Nordisk’s own self-pay ladder. [4] [7]
TrumpRx.gov, the federal drug-price site, works the same way for GLP-1s. As of October 25, 2026, it lists the Wegovy pill from $149, Wegovy pens from $199, Ozempic from $199, Zepbound from $299, and Foundayo from $149, which are the manufacturers’ self-pay prices. For Wegovy it provides a coupon to show at a retail pharmacy; for Foundayo and Zepbound it sends you to LillyDirect. [19] [20] [21]
That still makes these sites useful for a self-pay reader, but four caveats matter:
- the price can be tied to a specific dose
- it can be tied to an offer window, and several intro prices end December 31, 2026
- self-pay purchases happen outside your insurance and do not count toward your deductible or out-of-pocket limit [5] [20]
- it does not mean every pharmacy quote or future refill will match the posted price
So yes, discount-card and government-site pricing belong in the ranking. They just should not be mistaken for a separate, cheaper deal.
5. Telehealth prices only make sense when you split the membership fee from the medication fee
This is where a lot of “cheapest GLP-1” articles fall apart.
- Ro: the Body membership is $39 for the first month, then $149/month on a monthly plan or $74 to $99/month on prepaid 12-, 6-, or 3-month plans, with medication charged separately. Ro says its cash-pay GLP-1 prices match LillyDirect, NovoCare, and TrumpRx. [8]
- Found: the Branded GLP-1 Plan is $49 to $89/month with insurance or $99 to $149/month cash, depending on plan length, and the brand drug is billed separately. Found’s headline plans now include compounded semaglutide or tirzepatide, starting at $99/month with insurance or $169/month cash on 12-month prepaid terms. Insured members usually pay a visit copay of about $30 on top. [9] [10] [24]
- Noom: the full-dose GLP-1 Rx program starts at $129 for the first 4 weeks and $279/month after; the Microdose program starts at $79 and then $179/month. Noom says the semaglutide available through its GLP-1 Rx programs is compounded. Its branded-medication telehealth plan is $39 for a 30-day trial, then $129/month, with the drug not included. [11]
- Calibrate: the Metabolic Reset starts at $199/month with a 3-month commitment, while the company says GLP-1s for most commercially insured members should be $25/month or less after any deductible is met. [12]
The right comparison is never just “membership A vs membership B.” The right comparison is:
membership fee + medication fee + whether the product is full-dose FDA-approved brand medication + how much friction you are paying to avoid
6. Compounded and low-dose alternatives can be cheaper, but the cheap number is not the whole story
Some of the lowest sticker prices in this market come from paths that are not apples-to-apples with brand medication. FDA says compounded GLP-1 drugs are not FDA-approved, do not go through premarket review for safety, effectiveness, or quality, and should not be treated like interchangeable copies of the approved brands. FDA has also warned about dosing errors, warm-shipped product, and ingredient-quality concerns. [1]
In an April 1, 2026 update, FDA reminded compounders that neither semaglutide nor tirzepatide is on its drug shortage list or its 503B bulks list, which limits routine copying of the approved drugs. [25]
That does not make every low-cost alternative automatically wrong. It does mean you should separate two questions:
- Is this the cheapest number on the page?
- Is this the same product, oversight level, and risk profile as the brand medication I think I am comparing it to?
If the answer to question 2 is no, the comparison needs a warning label.
7. Clinical trials are a real path, but not a fast or universal one
Clinical trials belong on this list because they can reduce or eliminate some treatment costs, and they can include close research follow-up. But they are not a generic discount program.
NIH says clinical trials can involve extra care and attention from the trial staff, and it explicitly tells participants to ask what they may have to pay as part of the study. [13] ClinicalTrials.gov study pages are useful because they show the actual protocol, eligibility rules, and locations. In the STEP 7 semaglutide obesity study listing, participants were randomized to semaglutide or placebo and also received counseling on healthy food choices and physical activity. [14]
The honest framing is:
- this path can be low-cost or no-cost for some participants
- it can also involve screening failures, travel, and time burden
- what is covered depends on the protocol, not wishful thinking
8. International or mail-order import is not a dependable cheap workaround
This is the path readers ask about when U.S. prices feel absurd. FDA’s current position is still blunt: in most circumstances, it is illegal for individuals to import drugs into the U.S. for personal use. The agency describes only narrow situations where personnel may exercise discretion, such as a serious condition with no effective domestic commercial or clinical option, written personal-use affirmation, and generally no more than a three-month supply. [2]
That means international mail-order is not a stable cheap-access strategy. It is a legal and logistics risk with a much weaker reliability profile than the headline price suggests.
Which Cheap GLP-1 Path Fits Your Situation?
Use this if you need a next step, not another article:
- Do you have Medicare Part D? Check whether you meet the Medicare GLP-1 Bridge rules first, because the copay is $50 a month. [16] [17]
- Do you have commercial insurance? Check whether your plan covers the drug, then check the official Wegovy, Ozempic, Zepbound, or Foundayo savings card. [4] [5] [6] [18]
- Are you uninsured with low income and prescribed Ozempic? Check the Novo Nordisk PAP, which can provide Ozempic at $0 if your household income is at or below 200% of the federal poverty level. [3] [15]
- Do you want help fighting for coverage? Compare insurance-first programs such as Ro, Calibrate, or Found’s branded plan. [8] [12] [24]
- Do you need a self-pay brand option with clean public pricing? Compare the pill prices first (Wegovy pill and Foundayo from $149), then the pens (Wegovy from $199 for two intro months, Zepbound from $299), dose by dose. [4] [6] [18]
- Are you looking at a very low price that depends on compounding, microdosing, or foreign import? Stop and check the product type, the exact dose, and the legal or safety tradeoff before you treat that number as equivalent. [1] [2]
Real-World Cost Scenarios
These are the situations most readers actually fall into.
Scenario 1: You have good commercial coverage
The cheapest realistic path is often your ordinary plan copay plus a savings card. If your copay is $50, Wegovy’s card can bring it to $25; if it is $200, the card’s $100 monthly cap still leaves about $100. A prescribing service adds its own fee. With Found’s Branded GLP-1 Plan, for example, a $25 fill plus a $49 to $89 membership and a typical $30 visit copay comes to roughly $105 to $145 a month, not many hundreds. [4] [10] [24]
Scenario 2: You have coverage, but the deductible or prior auth process is the problem
This is where “insurance” stops feeling cheap. The membership fee may still be low, but the pharmacy price can stay high until the deductible is met or the PA clears. Calibrate is unusually direct here: the program costs $199/month, and the medication gets cheap only after the deductible math is out of the way. [12]
Scenario 3: You have Medicare Part D
If you meet the Bridge’s BMI rules and do not have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, the math is simple: $50 a month for Wegovy, the Zepbound KwikPen, or Foundayo through December 31, 2027, once your prescriber’s prior authorization is approved. If you do have one of those conditions, Medicare says your Part D plan might cover a GLP-1 under its own rules and costs. [16] [17]
Scenario 4: You are uninsured and want the cheapest full-brand path
Start with the published self-pay ladders, not the prettiest ad. As of October 2026, the lowest brand entry prices are the Wegovy pill and Foundayo at $149 a month. Price the dose your prescriber expects you to reach, not just the starter dose: the Wegovy pill label’s maintenance dose is 25 mg, which costs $299 a month; Foundayo is $299 at 9 mg and above; Wegovy pens are $349 a month at 2.4 mg; and Zepbound is $449 a month at 7.5 mg and above with on-time refills. [4] [6] [18] [23]
Scenario 5: You are uninsured and only need the lowest sticker price
That is the lane where microdose bundles, intro offers, or trial screening may look best on paper. Noom’s Microdose GLP-1 Rx program starts at $79 for the first 4 weeks and then costs $179/month, and Noom says the semaglutide in its program is compounded. That can look like a low-cost starting point, but it is not the same thing as an FDA-approved brand comparison. [11] [1]
Are Compounded or Imported GLP-1s a Safe Way to Save?
The market has two big cheap-price traps.
Trap 1: Treating compounded GLP-1 as interchangeable with brand medication
FDA’s warning page is clear enough that this should never be hand-waved away. If the low price depends on compounded GLP-1, you are not comparing equal products. As of May 31, 2026, FDA had received 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide. FDA says these events are likely underreported, and it cannot always tell whether the drug caused a given event. [1]
Trap 2: Treating foreign import as a routine workaround
The FDA import page makes the legal position clear: this is not a normal, dependable consumer access strategy in the U.S. [2]
The useful rule is:
A cheap price is good only if you can explain what exact product it buys, how you will keep getting it, and what risk you accepted to get there.
Bottom Line
If you want the cleanest one-sentence answer, it is this:
As of October 2026, the cheapest verified GLP-1 paths are a covered commercial plan plus a savings card (as little as $25 a month), the Medicare GLP-1 Bridge ($50 a month if you qualify), and brand self-pay pills that start at $149 a month, while Novo Nordisk’s $0 assistance program covers Ozempic only.
The more important answer is that “cheap” only helps if the comparison is honest. A $25 savings-card fill, a $50 Medicare Bridge copay, a $149 starter-dose pill, a $79 compounded microdose bundle, and a $299 self-pay Zepbound prescription are all different things. They solve different problems and carry different tradeoffs.
If you want more pricing breakdowns like this, join the newsletter. We track the manufacturer-price changes, telehealth-model shifts, and coverage updates that actually change what people pay.